Explore Our Biomarker Menu

Biomarker:

VEGF-C

Biological or Clinical Significance:

Vascular endothelial growth factor C (VEGF-C) is a protein that is a member of the platelet-derived growth factor / vascular endothelial growth factor (PDGF/VEGF) family. It is encoded in humans by the VEGFC gene, which is located on chromosome 4q34. The main function of VEGF-C is in lymphangiogenesis, where it acts on lymphatic endothelial cells (LECs) primarily via its receptor VEGFR-3 promoting survival, growth and migration.

VEGF-C is a dimeric, secreted protein, which undergoes a complex proteolytic maturation resulting in multiple processed forms. In a minority of lymphedema patients, the condition is caused by mutations in the VEGFC gene[16] and VEGF-C is a potential treatment for lymphedema. Also indirectly VEGF-C can be responsible for hereditary lymphedema: The rare Hennekam syndrome can result from the inability of the mutated CCBE1 to assist the ADAMTS3 protease in activating VEGF-C. Too much VEGF-C is implicated in tumor angiogenesis and metastasis. VEGF-C can act directly on blood vessels to promote tumor angiogenesis.

References:

Analyte:

VEGF-C

Matrix:

Human K2 EDTA Plasma

Status:

Validated

Sensitivity-LLOQ:

85.8 pg/mL

Sensitivity-ULOQ:

39,056 pg/mL

platform

MSD-ECL

Required Sample Volume

50 µL/well

Disease State:

Oncology

MSD Panel:

Angiogenesis Panel 1 (Human)

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.